4//SEC Filing
Cha Albert 4
Accession 0001567619-19-015022
CIK 0001348911other
Filed
Jul 18, 8:00 PM ET
Accepted
Jul 19, 6:38 PM ET
Size
14.4 KB
Accession
0001567619-19-015022
Insider Transaction Report
Form 4
CHA ALBERT
Director
Transactions
- Purchase
Common Stock
2019-07-19$17.84/sh+49,680$886,127→ 975,821 total(indirect: By Vivo Opportunity Fund, L.P.) - Purchase
Common Stock
2019-07-17$16.93/sh+220$3,724→ 104,551 total(indirect: By Vivo Capital Fund IX, L.P.) - Purchase
Common Stock
2019-07-19$17.68/sh+10,320$182,453→ 114,871 total(indirect: By Vivo Capital Fund IX, L.P.) - Purchase
Common Stock
2019-07-17$16.97/sh+1,060$17,991→ 926,141 total(indirect: By Vivo Opportunity Fund, L.P.)
Holdings
- 329,737(indirect: See Footnote)
Common Stock
Footnotes (7)
- [F1]The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.95 to $17.00 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]The shares are held of record by Vivo Opportunity Fund, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund, L.P. The voting members of Vivo Opportunity, LLC are Albert Cha, Gaurav Aggarwal, Shan Fu, Frank Kung, and Michael Chang, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares, except to the extent of such individual's pecuniary interest in the shares.
- [F3]The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.92 to $16.95 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F4]The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. The voting members of Vivo Capital IX, LLC are Frank Kung, Albert Cha, Shan Fu, Edgar Engleman and Chen Yu, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares, except to the extent of such individual's pecuniary interest in the shares.
- [F5]The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.56 to $17.70 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F6]The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.70 to $18.00 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F7]327,339 shares of Common Stock are held of record by Vivo Ventures Fund VI, L.P and 2,398 shares of Common Stock are held of record by Vivo Ventures VI Affiliates Fund, L.P. Vivo Ventures VI, LLC is the general partner of both Vivo Ventures Fund VI, L.P. and Vivo Ventures VI Affiliates Fund, L.P. The voting members of Vivo Ventures VI, LLC are Frank Kung, Albert Cha, and Edgar Engleman, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of these shares, except to the extent of such individual's pecuniary interests in the shares.
Documents
Issuer
KalVista Pharmaceuticals, Inc.
CIK 0001348911
Entity typeother
Related Parties
1- filerCIK 0001397906
Filing Metadata
- Form type
- 4
- Filed
- Jul 18, 8:00 PM ET
- Accepted
- Jul 19, 6:38 PM ET
- Size
- 14.4 KB